You are here: Industry Insights > Celgene

News List

Revlimid demonstrates positive phase III results in Indolent NHL GlobalData Healthcare
August 20, 2018
Celgene has announced positive new data for its leading blockbuster drug, Revlimid (lenalidomide), which earned revenues of $8.2bn in 2017.
Gilead investors see Celgene veteran Jackie Fouse as top pick for CEO spot: analyst fiercepharma
August 01, 2018
Biotech investors may still be getting over the shock of the departure of Gilead’s top two executives, but that hasn’t stopped analysts from speculating about who will be the troubled company’s next CEO.
Q2 results roundup - 27 July pharmatimes
July 30, 2018
Amgen has posted higher sales in Q2 2018 boosted by double-dgitig growth from some of its recently launched products. Revenue rose by 4% to $6.1 billion, above forecasts $5.7 billion. CEO Robert Bradway noted that "our two most recently launched products,
Celgene and Acceleron's blood disorder drug smashes endpoints at Phase 3 pharmafile
July 17, 2018
Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming that it demonstrated a “highly statistically significant improvement”
Celgene, Acceleron to file MDS therapy in the EU, US pharmatimes
July 04, 2018
Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.
Celgene pledges to limit price hikes—or does it? fiercepharma
July 04, 2018
Last October, as pharma companies ranging from Allergan to Sanofi were vowing to control price hikes...
Skyhawk, Celgene in Strategic Discovery and Development Pact contractpharma
July 03, 2018
Skyhawk Therapeutics, Inc. has entered a global, five-year strategic collaboration with Celgene Corp. to discover, develop and commercialize innovative small molecule treatments for patients with neurological diseases based on Skyhawk's STAR technology pl
Celgene and Skyhawk initiate five-year collaboration for neurological diseases pharmaceutical-technology
June 28, 2018
Celgene has entered into a five-year global strategic collaboration with drug discovery and development company Skyhawk Therapeutics with an upfront payment of $60m
Celgene bring in new CFO to steady the ship pharmafile
June 07, 2018
The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing serious questions over its pipeline and major worries about its lead candidate, ozanimod.
Evotec and Celgene Expand IPSC Collaboration to Include Additional Cell Lines firstwordpharma
May 30, 2018
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that the Company will receive a $ 6 m payment from Celgene following Celgene's decision to expand the collaboration to include additional cell lines.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page